Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance

E. Krepsova, I. Tycova, A. Sekerkova, P. Wohlfahrt, P. Hruba, I. Striz, B. Sawitzki, O. Viklicky,

. 2015 ; 16 (-) : 146. [pub] 20150819

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16009995

Grant support
NT14102 MZ0 CEP Register

BACKGROUND: Induction therapy can improve kidney transplantation (KTx) outcomes, but little is known about the mechanisms underlying its effects. METHODS: The mRNA levels of T cell-related genes associated with tolerance or rejection (CD247, GZMB, PRF1, FOXP3, MAN1A1, TCAIM, and TLR5) and lymphocyte subpopulations were monitored prospectively in the peripheral blood of 60 kidney transplant recipients before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx. Patients were treated with calcineurin inhibitor-based triple immunosuppression and induction with rabbit anti-thymocyte globulin (rATG, n = 24), basiliximab (n = 17), or without induction (no-induction, n = 19). A generalized linear mixed model with gamma distribution for repeated measures, adjusted for rejection, recipient/donor age and delayed graft function, was used for statistical analysis. RESULTS: rATG treatment caused an intense reduction in all T cell type population and natural killer (NK) cells within 7 days, then a slow increase and repopulation was observed. This was also noticed in the expression levels of CD247, FOXP3, GZMB, and PRF1. The basiliximab group exhibited higher CD247, GZMB, FOXP3 and TCAIM mRNA levels and regulatory T cell (Treg) counts than the no-induction group. The levels of MAN1A1 and TLR5 mRNA expressions were increased, whereas TCAIM decreased in the rATG group as compared with those in the no-induction group. CONCLUSION: The rATG induction therapy was associated with decreased T and NK cell-related transcript levels and with upregulation of two rejection-associated transcripts (MAN1A1 and TLR5) shortly after KTx. Basiliximab treatment was associated with increased absolute number of Treg cells, and increased level of FOXP3 and TCAIM expression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16009995
003      
CZ-PrNML
005      
20191118093713.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12882-015-0141-2 $2 doi
024    7_
$a 10.1186/s12882-015-0141-2 $2 doi
035    __
$a (PubMed)26286066
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Krepsova, Eva $u Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. eva.krepsova@ikem.cz.
245    10
$a Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance / $c E. Krepsova, I. Tycova, A. Sekerkova, P. Wohlfahrt, P. Hruba, I. Striz, B. Sawitzki, O. Viklicky,
520    9_
$a BACKGROUND: Induction therapy can improve kidney transplantation (KTx) outcomes, but little is known about the mechanisms underlying its effects. METHODS: The mRNA levels of T cell-related genes associated with tolerance or rejection (CD247, GZMB, PRF1, FOXP3, MAN1A1, TCAIM, and TLR5) and lymphocyte subpopulations were monitored prospectively in the peripheral blood of 60 kidney transplant recipients before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx. Patients were treated with calcineurin inhibitor-based triple immunosuppression and induction with rabbit anti-thymocyte globulin (rATG, n = 24), basiliximab (n = 17), or without induction (no-induction, n = 19). A generalized linear mixed model with gamma distribution for repeated measures, adjusted for rejection, recipient/donor age and delayed graft function, was used for statistical analysis. RESULTS: rATG treatment caused an intense reduction in all T cell type population and natural killer (NK) cells within 7 days, then a slow increase and repopulation was observed. This was also noticed in the expression levels of CD247, FOXP3, GZMB, and PRF1. The basiliximab group exhibited higher CD247, GZMB, FOXP3 and TCAIM mRNA levels and regulatory T cell (Treg) counts than the no-induction group. The levels of MAN1A1 and TLR5 mRNA expressions were increased, whereas TCAIM decreased in the rATG group as compared with those in the no-induction group. CONCLUSION: The rATG induction therapy was associated with decreased T and NK cell-related transcript levels and with upregulation of two rejection-associated transcripts (MAN1A1 and TLR5) shortly after KTx. Basiliximab treatment was associated with increased absolute number of Treg cells, and increased level of FOXP3 and TCAIM expression.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a antigeny CD3 $x genetika $7 D017252
650    _2
$a antilymfocytární sérum $x terapeutické užití $7 D000961
650    _2
$a inhibitory kalcineurinu $x terapeutické užití $7 D065095
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a forkhead transkripční faktory $x genetika $7 D051858
650    _2
$a exprese genu $x účinky léků $7 D015870
650    _2
$a rejekce štěpu $x genetika $x imunologie $x prevence a kontrola $7 D006084
650    _2
$a granzymy $x genetika $7 D053804
650    _2
$a lidé $7 D006801
650    _2
$a imunologická tolerance $x účinky léků $x genetika $7 D007108
650    _2
$a imunosupresivní léčba $x metody $7 D007165
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a indukční chemoterapie $x metody $7 D060828
650    _2
$a transplantace ledvin $x metody $7 D016030
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mannosidasy $x genetika $7 D008361
650    _2
$a lidé středního věku $7 D008875
650    _2
$a NKT buňky $x účinky léků $x imunologie $7 D055611
650    _2
$a perforin $x genetika $7 D054353
650    _2
$a prospektivní studie $7 D011446
650    _2
$a messenger RNA $x krev $7 D012333
650    _2
$a rekombinantní fúzní proteiny $x terapeutické užití $7 D011993
650    _2
$a regulační T-lymfocyty $x účinky léků $x imunologie $7 D050378
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Týcová, Irena $u Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. irena.tycova@ikem.cz. $7 xx0227633
700    1_
$a Sekerková, Alena $u Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. alena.sekerkova@ikem.cz. $7 xx0204822
700    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology, Cardiology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. peter.wohlfahrt@ikem.cz. $7 xx0230851
700    1_
$a Hruba, Petra $u Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. petra.hruba@ikem.cz.
700    1_
$a Stříž, Ilja, $u Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. ilja.striz@ikem.cz. $d 1958- $7 jn20000402309
700    1_
$a Sawitzki, Birgit $u Institute of Medical Immunology and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Charité University Medicine, Berlin, Germany. birgit.sawitzki@charite.de.
700    1_
$a Viklický, Ondřej, $u Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. ondrej.viklicky@ikem.cz. Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Videnska 1958, 14021, Prague, Czech Republic. ondrej.viklicky@ikem.cz. Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. ondrej.viklicky@ikem.cz. $d 1966- $7 nlk20050170291
773    0_
$w MED00008194 $t BMC nephrology $x 1471-2369 $g Roč. 16, č. - (2015), s. 146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26286066 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191118093953 $b ABA008
999    __
$a ok $b bmc $g 1113424 $s 934363
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 16 $c - $d 146 $e 20150819 $i 1471-2369 $m BMC nephrology $n BMC Nephrol $x MED00008194
GRA    __
$a NT14102 $p MZ0
LZP    __
$a Pubmed-20160408
Back

Find record

Citation metrics

Archiving options